Inflammation and cancer-related fatigue: Mechanisms, contributing factors, and treatment implications

Brain, Behavior, and Immunity

Volumn 30, Issue SUPPL., 2013, Pages

  Bower, Julienne E ^a,b,c   Lamkin, Donald M ^b  

^a UCLA Department of Psychology   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; Fatigue; Inflammation

Indexed keywords

GLUCOCORTICOID RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA;

ANIMAL MODEL; BODY MASS; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURVIVOR; COGNITIVE THERAPY; DEPRESSION; GENE EXPRESSION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; ILLNESS BEHAVIOR; IMMOBILIZATION; INFLAMMATION; IONIZING RADIATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; WHOLE BODY RADIATION;

ANIMALS; FATIGUE; HUMANS; INFLAMMATION; NEOPLASMS; RISK FACTORS;

EID: 84875371149     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2012.06.011     Document Type: Review

References (136)

1. Aggarwal B.B. Nuclear factor-κB: the enemy within. Cancer Cell 2004, 6:203-208.
2. Aggarwal B.B., Vijayalekshmi R.V., Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin. Cancer Res. 2009, 15(2):425-430.
3. Ahlberg K., Ekman T., Gaston-Johansson F. Levels of fatigue compared to levels of cytokines and hemoglobin during pelvic radiotherapy: a pilot study. Biol. Res. Nurs. 2004, 5(3):203-210.
4. Alexander S., Minton O., Andrews P., Stone P. A comparison of the characteristics of disease-free breast cancer survivors with or without cancer-related fatigue syndrome. Eur. J. Cancer 2009, 45(3):384-392.
5. Alfano, C.M., Imayama, I., Neuhouser, M.L., Kiecolt-Glaser, J.K., Wilder Smith, A., Meeske, K., McTiernan, A., Bernstein, L., Baumgartner, K.B., Ulrich, C.M., Ballard-Barbash, R., 2012. Fatigue, Inflammation, and -ë-3 and -ë-6 Fatty Acid Intake Among Breast Cancer Survivors. J. Clin. Oncol. 30 (12), 1280-1287.
6. Andrykowski M.A., Curran S.L., Lightner R. Off-treatment fatigue in breast cancer survivors: a controlled comparison. J. Behav. Med. 1998, 21(1):1-18.
7. Andrykowski M.A., Schmidt J.E., Salsman J.M., Beacham A.O., Jacobsen P.B. Use of a case definition approach to identify cancer-related fatigue in women undergoing adjuvant therapy for breast cancer. J. Clin. Oncol. 2005, 23(27):6613-6622.
8. Antoni M.H., Lutgendorf S.K., Blomberg B., Carver C.S., Lechner S., Diaz A., Stagl J., Arevalo J.M., Cole S.W. Cognitive-behavioral stress management reverses anxiety-related leukocyte transcriptional dynamics. Biol. Psychiatry 2012, 71(4):366-372.
9. Aouizerat B.E., Dodd M., Lee K., West C., Paul S.M., Cooper B.A., Wara W., Swift P., Dunn L.B., Miaskowski C. Preliminary evidence of a genetic association between tumor necrosis factor alpha and the severity of sleep disturbance and morning fatigue. Biol. Res. Nurs. 2009, 11(1):27-41.
10. Appels A., Bar F.W., Bar J., Bruggeman C., de Baets M. Inflammation, depressive symptomtology, and coronary artery disease. Psychosom. Med. 2000, 62(5):601-605.
11. Arpin D., Perol D., Blay J.Y., Falchero L., Claude L., Vuillermoz-Blas S., Martel-Lafay I., Ginestet C., Alberti L., Nosov D., Etienne-Mastroianni B., Cottin V., Perol M., Guerin J.C., Cordier J.F., Carrie C. Early variations of circulating interleukin-6 and interleukin-10 levels during thoracic radiotherapy are predictive for radiation pneumonitis. J. Clin. Oncol. 2005, 23(34):8748-8756.
12. Borowski T., Kokkinidis L., Merali Z., Anisman H. Lipopolysaccharide, central in vivo biogenic amine variations, and anhedonia. NeuroReport 1998, 9:3797-3802.
13. Bower J.E. Cancer-related fatigue: links with inflammation in cancer patients and survivors. Brain Behav. Immun. 2007, 21(7):863-871.
14. Bower J.E., Ganz P.A., Aziz N. Altered cortisol response to psychologic stress in breast cancer survivors with persistent fatigue. Psychosom. Med. 2005, 67(2):277-280.
15. Bower J.E., Ganz P.A., Aziz N., Fahey J.L. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom. Med. 2002, 64(4):604-611.
16. Bower J.E., Ganz P.A., Aziz N., Fahey J.L., Cole S.W. T-cell homeostasis in breast cancer survivors with persistent fatigue. J. Natl. Cancer Inst. 2003, 95(15):1165-1168.
17. Bower J.E., Ganz P.A., Aziz N., Olmstead R., Irwin M.R., Cole S.W. Inflammatory responses to psychological stress in fatigued breast cancer survivors: relationship to glucocorticoids. Brain Behav. Immun. 2007, 21(3):251-258.
18. Bower J.E., Ganz P.A., Desmond K.A., Bernaards C., Rowland J.H., Meyerowitz B.E., Belin T.R. Fatigue in long-term breast carcinoma survivors: a longitudinal investigation. Cancer 2006, 106(4):751-758.
19. Bower J.E., Ganz P.A., Desmond K.A., Rowland J.H., Meyerowitz B.E., Belin T.R. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J. Clin. Oncol. 2000, 18(4):743-753.
20. Bower J.E., Ganz P.A., Dickerson S.S., Petersen L., Aziz N., Fahey J.L. Diurnal cortisol rhythm and fatigue in breast cancer survivors. Psychoneuroendocrinology 2005, 30(1):92-100.
21. Bower J.E., Ganz P.A., Irwin M.R., Arevalo J.M., Cole S.W. Fatigue and gene expression in human leukocytes: increased NF-kappaB and decreased glucocorticoid signaling in breast cancer survivors with persistent fatigue. Brain Behav. Immun. 2011, 25(1):147-150.
22. Bower J.E., Ganz P.A., Irwin M.R., Kwan L., Breen E.C., Cole S.W. Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism?. J. Clin. Oncol. 2011, 29(26):3517-3522.
23. Bower J.E., Ganz P.A., Tao M.L., Hu W., Belin T.R., Sepah S., Cole S., Aziz N. Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer. Clin. Cancer Res. 2009, 15(17):5534-5540.
24. Bower, J.E., Garet, D., Sternlieb, B., Ganz, P.A., Irwin, M.R., Olmstead, R, Greendale, G., 2011c. Yoga for persistent fatigue in breast cancer survivors: A randomized controlled trial. Cancer. [Epub ahead of print].
25. Broeckel J.A., Jacobsen P.B., Horton J., Balducci L., Lyman G.H. Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J. Clin. Oncol. 1998, 16(5):1689-1696.
26. Brush J., Lipnick S.L., Phillips T., Sitko J., McDonald J.T., McBride W.H. Molecular mechanisms of late normal tissue injury. Semin. Radiat. Oncol. 2007, 17(2):121-130.
27. Capuron L., Gumnick J.F., Musselman D.L., Lawson D.H., Reemsnyder A., Nemeroff C.B., Miller A.H. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002, 26:643-652.
28. Capuron L., Miller A.H. Cytokines and psychopathology: lessons learned from interferon-alpha. Biol. Psychiatry 2004, 56:819-824.
29. Capuron L., Pagnoni G., Demetrashvili M.F., Lawson D.H., Fornwalt F.B., Woolwine B., Berns G.S., Nemeroff C.B., Miller A.H. Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacology 2007, 32:2384-2392.
30. Capuron L., Raison C.L., Musselman D.L., Lawson D.H., Nemeroff C.B., Miller A.H. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am. J. Psychiatry 2003, 160(7):1342-1345.
31. Carlo-Stella N., Badulli C., De Silvestri A., Bazzichi L., Martinetti M., Lorusso L., Bombardieri S., Salvaneschi L., Cuccia M. A first study of cytokine genomic polymorphisms in CFS: positive association of TNF-857 and IFN gamma 874 rare alleles. Clin. Exp. Rheumatol. 2006, 24(2):179-182.
32. Catley D., Kaell A.T., Kirschbaum C., Stone A.A. A naturalistic evaluation of cortisol secretion in persons with fibromyalgia and rheumatoid arthritis. Arthritis Care Res. 2000, 13(1):51-61.
33. Cavaletti G., Marzorati L., Bogliun G., Colombo N., Marzola M., Pittelli M.R., Tredici G. Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer 1992, 69:203-207.
34. Cella D., Davis K., Breitbart W., Curt G. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J. Clin. Oncol. 2001, 19(14):3385-3391.
35. Cella D., Peterman A., Passik S., Jacobsen P., Breitbart W. Progress toward guidelines for the management of fatigue. Oncology (Huntingt) 1998, 12(11A):369-377.
36. Cancer chemotherapy and biotherapy: Principles and practices 2006, Lippincott, Philadelphia. B.A. Chabner, D.L. Longo (Eds.).
37. Cleare A.J. The neuroendocrinology of chronic fatigue syndrome. Endocr. Rev. 2003, 24(2):236-252.
38. Cole S.W., Hawkley L.C., Arevalo J.M., Sung C.Y., Rose R.M., Cacioppo J.T. Social regulation of gene expression in human leukocytes. Genome Biol. 2007, 8(9):R189.
39. Collado-Hidalgo A., Bower J.E., Ganz P.A., Cole S.W., Irwin M.R. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin. Cancer Res. 2006, 12(9):2759-2766.
40. Collado-Hidalgo, A., Bower, JE., Ganz, PA., Irwin, MR., Cole, S.W., 2008. Cytokine gene polymorphisms and fatigue in breast cancer survivors: Early findings. Brain Behav. Immun. 22 (8), 1197-1200.
41. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
42. Crofford L.J., Pillemer S.R., Kalogeras K.T., Cash J.M., Michelson D., Kling M.A., Sternberg E.M., Gold P.W., Chrousos G.P., Wilder R.L. Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum. 1994, 37(11):1583-1592.
43. Danese A., Pariante C.M., Caspi A., Taylor A., Poulton R. Childhood maltreatment predicts adult inflammation in a life-course study. Proc. Natl. Acad. Sci. USA 2007, 104(4):1319-1324.
44. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9(1):46-56.
45. DeMichele A., Gray R., Horn M., Chen J., Aplenc R., Vaughan W.P., Tallman M.S. Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer. Cancer Res. 2009, 69(10):4184-4191.
46. Donovan K.A., Jacobsen P.B., Andrykowski M.A., Winters E.M., Balducci L., Malik U., Kenady D., McGrath P. Course of fatigue in women receiving chemotherapy and/or radiotherapy for early stage breast cancer. J. Pain Symptom. Manage. 2004, 28(4):373-380.
47. Donovan K.A., Small B.J., Andrykowski M.A., Munster P., Jacobsen P.B. Utility of a cognitive-behavioral model to predict fatigue following breast cancer treatment. Health Psychol. 2007, 26(4):464-472.
48. Dunlop B.W., Nemeroff C.B. The role of dopamine in the pathophysiology of depression. Arch. Gen. Psychiatry 2007, 64:327-337.
49. Fagundes, C.P., Lindgren, M.E., Shapirom C.L., Kiecolt-Glaserm J.K., 2012. Child maltreatment and breast cancer survivors: Social support makes a difference for quality of life, fatigue and cancer stress. Eur. J. Cancer. 48, 728-736.
50. Fagundes C.P., Glaser R., Alfano C.M., Bennett J.M., Povoski S.P., Lipari A.M., Agnese D.M., Yee L.D., Carson W.E., Farrar W.B., Malarkey W.B., Kiecolt-Glaser J.K. Fatigue and herpesvirus latency in women newly diagnosed with breast cancer. Brain Behav. Immun. 2012, 26(3):394-400.
51. Fairey A.S., Courneya K.S., Field C.J., Bell G.J., Jones L.W., Martin B.S., Mackey J.R. Effect of exercise training on C-reactive protein in postmenopausal breast cancer survivors: a randomized controlled trial. Brain Behav. Immun. 2005, 19(5):381-388.
52. Frenois F., Moreau M., O'Connor J., Lawson M., Micon C., Lestage J., Kelley K.W., Dantzer R., Castanon N. Lipopolysaccharide induces delayed FosB/DeltaFosB immunostaining within the mouse extended amygdala, hippocampus and hypothalamus, that parallel the expression of depressive-like behavior. Psychoneuroendocrinology 2007, 32:516-531.
53. Geinitz H., Zimmermann F.B., Stoll P., Thamm R., Kaffenberger W., Ansorg K., Keller M., Busch R., van Beuningen D., Molls M. Fatigue, serum cytokine levels, and blood cell counts during radiotherapy of patients with breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 2001, 51(3):691-698.
54. Gielissen M.F., Verhagen S., Witjes F., Bleijenberg G. Effects of cognitive behavior therapy in severely fatigued disease-free cancer patients compared with patients waiting for cognitive behavior therapy: a randomized controlled trial. J. Clin. Oncol. 2006, 24(30):4882-4887.
55. Glaser R., Padgett D.A., Litsky M.L., Baiocchi R.A., Yang E.V., Chen M., Yeh P.E., Klimas N.G., Marshall G.D., Whiteside T., Herberman R., Kiecolt-Glaser J., Williams M.V. Stress-associated changes in the steady-state expression of latent Epstein-Barr virus: implications for chronic fatigue syndrome and cancer. Brain Behav. Immun. 2005, 19(2):91-103.
56. Godbout J.P., Moreau M., Lestage J., Chen J., Sparkman N.L., O' Connor J., Castanon N., Kelley K.W., Dantzer R., Johnson R.W. Aging exacerbates depressive-like behavior in mice in response to activation of the peripheral innate immune system. Neuropsychopharmacology 2008, 33:2341-2351.
57. Gothelf D., Apter A., Reidman J., Brand-Gothelf A., Bloch Y., Gal G., Kikinzon L., Tyano S., Weizman R., Ratzoni G. Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. J. Neural. Trans. 2003, 110:545-560.
58. Greenberg D.B., Gray J.L., Mannix C.M., Eisenthal S., Carey M. Treatment-related fatigue and serum interleukin-1 levels in patients during external beam irradiation for prostate cancer. J. Pain Symptom. Manage. 1993, 8(4):196-200.
59. Groenvold M., Petersen M.A., Idler E., Bjorner J.B., Fayers P.M., Mouridsen H.T. Psychological distress and fatigue predicted recurrence and survival in primary breast cancer patients. Breast Cancer Res. Treat. 2007, 105:209-219.
60. Haveman J., Geerdink A.G., Rodermond H.M. TNF, IL-1 and IL-6 in circulating blood after total-body and localized irradiation in rats. Oncol. Rep. 1998, 5:679-683.
61. Heim C., Wagner D., Maloney E., Papanicolaou D.A., Solomon L., Jones J.F., Unger E.R., Reeves W.C. Early adverse experience and risk for chronic fatigue syndrome: results from a population-based study. Arch. Gen. Psychiatry 2006, 63(11):1258-1266.
62. Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 2009, 71(2):171-186.
63. Irwin M. Effects of sleep and sleep loss on immunity and cytokines. Brain Behav. Immun. 2002, 16(5):503-512.
64. Jacobsen P.B., Donovan K.A., Weitzner M.A. Distinguishing fatigue and depression in patients with cancer. Semin. Clin. Neuropsychiatry 2003, 8(4):229-240.
65. Jim, H.S., Park, J.Y., Permuth-Wey, J., Rincon, M.A., Phillips, K.M., Small, B.J., Jacobsen, P.B., 2012. Genetic Predictors of Fatigue in Prostate Cancer Patients Treated with Androgen Deprivation Therapy: Preliminary Findings. Brain Behav. Immun. [Epub ahead of print].
66. Juengling F.D., Ebert D., Gut O., Engelbrecht M.A., Rasenack J., Nitzsche E.U., Bauer J., Lieb K. Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology 2000, 152:383-389.
67. Kangas M., Bovbjerg D.H., Montgomery G.H. Cancer-related fatigue: a systematic and meta-analytic review of non-pharmacological therapies for cancer patients. Psychol. Bull. 2008, 134(5):700-741.
68. Kent S., Bluthe R.M., Kelley K.W., Dantzer R. Sickness behavior as a new target for drug development. Trends Pharmacol. Sci. 1992, 13(1):24-28.
69. Khayyal M.T., El-Ghazaly M.A., El-Hazek R.M., Nada A.S. The effects of celecoxib, a COX-2 selective inhibitor, on acute inflammation induced in irradiated rats. Inflammopharmacology 2009, 17:255-266.
70. Kiecolt-Glaser J.K., Christian L., Preston H., Houts C.R., Malarkey W.B., Emery C.F., Glaser R. Stress, inflammation, and yoga practice. Psychosom. Med. 2010, 72(2):113-121.
71. Kiecolt-Glaser J.K., Preacher K.J., MacCallum R.C., Atkinson C., Malarkey W.B., Glaser R. Chronic stress and age-related increases in the proinflammatory cytokine IL-6. Proc. Natl. Acad. Sci. USA 2003, 100(15):9090-9095.
72. King G.L., Landauer M.R. Effects of zacopride and BMY25801 (batanopride) on radiation-induced emesis and locomotor behavior in the ferret. J. Pharmacol. Exp. Ther. 1990, 253:1026-1033.
73. Kumai T., Tateishi T., Tanaka M., Watanabe M., Shimizu H., Kobayashi S. Effect of interferon-alpha on tyrosine hydroxylase and catecholamine levels in the brain of rats. Life Sci. 2000, 67:663-669.
74. Kuo C.P., Wu C.L., Ho H.T., Chen C.G., Liu S.I., Lu Y.T. Detection of cytomegalovirus reactivation in cancer patients receiving chemotherapy. Clin. Microbiol. Infect. 2008, 14(3):221-227.
75. Lamkin D.M., Lutgendorf S.K., Lubaroff D., Sood A.K., Beltz T.G., Johnson A.K. Cancer induces inflammation and depressive-like behavior in the mouse: modulation by social housing. Brain Behav. Immun. 2011, 25:555-564.
76. Landmark-Hoyvik H., Reinertsen K.V., Loge J.H., Fossa S.D., Borresen-Dale A.L., Dumeaux V. Alterations of gene expression in blood cells associated with chronic fatigue in breast cancer survivors. Pharmacogenomics J. 2009, 9(5):333-340.
77. Lawrence D.P., Kupelnick B., Miller K., Devine D., Lau J. Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. J. Natl. Cancer Inst. Monogr. 2004, (32):40-50.
78. Levant B., Grigoriadis D.E., DeSouza E.B. Characterization of [3H]quinpirole binding to D2-like dopamine receptors in rat brain. J. Pharmacol. Exp. Ther. 1992, 262:929-935.
79. Lutgendorf S.K., Weinrib A.Z., Penedo F., Russell D., DeGeest K., Costanzo E.S., Henderson P.J., Sephton S.E., Rohleder N., Lucci J.A., Cole S., Sood A.K., Lubaroff D.M. Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J. Clin. Oncol. 2008, 26(29):4820-4827.
80. Malik N.M., Liu Y.L., Cole N., Sanger G.J., Andrews P.L. Differential effects of dexamethasone, ondansetron and a tachykinin NK1 receptor antagonist (GR205171) on cisplatin-induced changes in behaviour, food intake, pica and gastric function in rats. Eur. J. Pharmacol. 2007, 555:164-173.
81. Malik N.M., Moore G.B., Smith G., Liu Y.L., Sanger G.J., Andrews P.L. Behavioural and hypothalamic molecular effects of the anti-cancer agent cisplatin in the rat: a model of chemotherapy-related malaise?. Pharmacol. Biochem. Behav. 2006, 83:9-20.
82. McCauley J., Kern D.E., Kolodner K., Dill L., Schroeder A.F., DeChant H.K., Ryden J., Derogatis L.R., Bass E.B. Clinical characteristics of women with a history of childhood abuse: unhealed wounds. JAMA 1997, 277(17):1362-1368.
83. McEwen B.S., Biron C.A., Brunson K.W., Bulloch K., Chambers W.H., Dhabhar F.S., Goldfarb R.H., Kitson R.P., Miller A.H., Spencer R.L., Weiss J.M. The role of adrenocorticoids as modulators of immune function in health and disease: neural, endocrine and immune interactions. Brain Res. Brain Res. Rev. 1997, 23(1-2):79-133.
84. Meyer J.S., Quenzer L.F. Psychopharmacology: Drugs, The Brain, and Behavior 2005, Sinauer Associates, Sunderland, MA.
85. Meyers C.A., Albitar M., Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2005, 104(4):788-793.
86. Miaskowski C., Dodd M., Lee K., West C., Paul S.M., Cooper B.A., Wara W., Swift P.S., Dunn L.B., Aouizerat B.E. Preliminary evidence of an association between a functional interleukin-6 polymorphism and fatigue and sleep disturbance in oncology patients and their family caregivers. J. Pain Symp. Manage. 2010, 40(4):531-544.
87. Miller A.H. Norman Cousins Lecture. Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface. Brain Behav. Immun. 2009, 23:149-158.
88. Miller A.H., Ancoli-Israel S., Bower J.E., Capuron L., Irwin M.R. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J. Clin. Oncol. 2008, 26(6):971-982.
89. Miller G.E., Chen E., Fok A.K., Walker H., Lim A., Nicholls E.F., Cole S., Kobor M.S. Low early-life social class leaves a biological residue manifested by decreased glucocorticoid and increased proinflammatory signaling. Proc. Natl. Acad. Sci. USA 2009, 106(34):14716-14721.
90. Miller G.E., Chen E., Sze J., Marin T., Arevalo J.M., Doll R., Ma R., Cole S.W. A functional genomic fingerprint of chronic stress in humans: blunted glucocorticoid and increased NF-kappaB signaling. Biol. Psychiatry 2008, 64(4):266-272.
91. Miller G.E., Freedland K.E., Duntley S., Carney R.M. Relation of depressive symptoms to C-reactive protein and pathogen burden (cytomegalovirus, herpes simplex virus, Epstein-Barr virus) in patients with earlier acute coronary syndromes. Am. J. Cardiol. 2005, 95(3):317-321.
92. Mills P.J., Parker B., Dimsdale J.E., Sadler G.R., Ancoli-Israel S. The relationship between fatigue and quality of life and inflammation during anthracycline-based chemotherapy in breast cancer. Biol. Psychol. 2005, 69(1):85-96.
93. Mills P.J., Parker B., Jones V., Adler K.A., Perez C.J., Johnson S., Cohen-Zion M., Marler M., Sadler G.R., Dimsdale J.E., Ancoli-Israel S. The effects of standard anthracycline-based chemotherapy on soluble ICAM-1 and vascular endothelial growth factor levels in breast cancer. Clin. Cancer Res. 2004, 10(15):4998-5003.
94. Minton O., Richardson A., Sharpe M., Hotopf M., Stone P.C. Psychostimulants for the management of cancer-related fatigue: a systematic review and meta-analysis. J. Pain Symptom Manage. 2011, 41(4):761-767.
95. Mollman J.E. Cisplatin neurotoxicity. N. Engl. J. Med. 1990, 322(2):126-127.
96. Monk J.P., Phillips G., Waite R., Kuhn J., Schaaf L.J., Otterson G.A., Guttridge D., Rhoades C., Shah M., Criswell T., Caligiuri M.A., Villalona-Calero M.A. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J. Clin. Oncol. 2006, 24(12):1852-1859.
97. Morrow G.R., Hickok J.T., Roscoe J.A., Raubertas R.F., Andrews P.L., Flynn P.J., Hynes H.E., Banerjee T.K., Kirshner J.J., King D.K. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J. Clin. Oncol. 2003, 21(24):4635-4641.
98. Musselman D.L., Lawson D.H., Gumnick J.F., Manatunga A.K., Penna S., Goodkin R.S., Greiner K., Nemeroff C.B., Miller A.H. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N. Engl. J. Med. 2001, 344:961-966.
99. Nater U.M., Youngblood L.S., Jones J.F., Unger E.R., Miller A.H., Reeves W.C., Heim C. Alterations in diurnal salivary cortisol rhythm in a population-based sample of cases with chronic fatigue syndrome. Psychosom. Med. 2008, 70(3):298-305.
100. Nazmi A., Diez-Roux A.V., Jenny N.S., Tsai M.Y., Szklo M., Aiello A.E. The influence of persistent pathogens on circulating levels of inflammatory markers: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis. BMC. Public Health 2010, 10:706.
101. O'Connor J.C., Lawson M.A., Andre C., Moreau M., Lestage J., Castanon N., Kelley K.W., Dantzer R. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol. Psychiatry 2009, 14:511-522.
102. O'Connor M.F., Bower J.E., Cho H.J., Creswell J.D., Dimitrov S., Hamby M.E., Hoyt M.A., Martin J.L., Robles T.F., Sloan E.K., Thomas K.S., Irwin M.R. To assess, to control, to exclude: effects of biobehavioral factors on circulating inflammatory markers. Brain Behav. Immun. 2009, 23:887-897.
103. Orre I.J., Murison R., Dahl A.A., Ueland T., Aukrust P., Fossσ S.D. Levels of circulating interleukin-1 receptor antagonist and C-reactive protein in long-term survivors of testicular cancer with chronic cancer-related fatigue. Brain Behav. Immun. 2009, 23(6):868-874.
104. Orre I.J., Reinertsen K.V., Aukrust P., Dahl A.A., Foss+ñ S.D., Ueland T., Murison R. Higher levels of fatigue are associated with higher CRP levels in disease-free breast cancer survivors. J. Psychosom. Res. 2011, 71(3):136-141.
105. Pace T.W., Mletzko T.C., Alagbe O., Musselman D.L., Nemeroff C.B., Miller A.H., Heim C.M. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am. J. Psychiatry 2006, 163(9):1630-1633.
106. Poulson M.J. Not just tired. J. Clin. Oncol. 2001, 19(21):4180-4181.
107. Piraino, B., Vollmer-Conna, U., Lloyd, AR., 2012. Genetic associations of fatigue and other symptom domains of the acute sickness response to infection. Brain, Behav. Immun. 26 (4), 552-558.
108. Pullen P.R., Nagamia S.H., Mehta P.K., Thompson W.R., Benardot D., Hammoud R., Parrott J.M., Sola S., Khan B.V. Effects of yoga on inflammation and exercise capacity in patients with chronic heart failure. J. Card Fail. 2008, 14(5):407-413.
109. Pusztai L., Mendoza T.R., Reuben J.M., Martinez M.M., Willey J.S., Lara J., Syed A., Fritsche H.A., Bruera E., Booser D., Valero V., Arun B., Ibrahim N., Rivera E., Royce M., Cleeland C.S., Hortobagyi G.N. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 2004, 25(3):94-102.
110. Ray M.A., Trammell R.A., Verhulst S., Ran S., Toth L.A. Development of a mouse model for assessing fatigue during chemotherapy. Comp. Med. 2011, 61:119-130.
111. Raison C.L., Miller A.H. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am. J. Psychiatry 2003, 160(9):1554-1565.
112. Raison C.L., Capuron L., Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006, 27(1):24-31.
113. Rausch S.M., Clark M.M., Patten C., Liu H., Felten S., Li Y., Sloan J., Yang P. Relationship between cytokine gene single nucleotide polymorphisms and symptom burden and quality of life in lung cancer survivors. Cancer 2010, 116(17):4103-4113.
114. Reinertsen K.V., Grenaker Alnaes G.I., Landmark-Hoyvik H., Loge J.H., Wist E., Kristensen V.N., Fossa S.D., Edvardsen H. Fatigued breast cancer survivors and gene polymorphisms in the inflammatory pathway. Brain, Behav. Immun. 2011, 25(7):1376-1383.
115. Rotstein S., Blomgren H., Petrini B., Wasserman J., Baral E. Long term effects on the immune system following local radiation therapy for breast cancer I. Cellular composition of the peripheral blood lymphocyte population. Int. J. Radiat. Oncol. Biol. Phys. 1985, 11(5):921-925.
116. Rowinsky E.K., Eisenhauer E.A., Chaudhry V., Arbuck S.G., Donehower R.C. Clinical toxicities encountered with paclitaxel (Taxol). Semin. Oncol. 1993, 20:1-15.
117. Schubert C., Hong S., Natarajan L., Mills P.J., Dimsdale J.E. The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav. Immun. 2007, 21(4):413-427.
118. Seruga B., Zhang H., Bernstein L.J., Tannock I.F. Cytokines and their relationship to the symptoms and outcome of cancer. Nat. Rev. Cancer 2008, 8(11):887-899.
119. Servaes P., Gielissen M.F., Verhagen S., Bleijenberg G. The course of severe fatigue in disease-free breast cancer patients: a longitudinal study. Psychooncology 2006, 16(9):787-795.
120. Servaes P., Verhagen C., Bleijenberg G. Fatigue in cancer patients during and after treatment: prevalence, correlates and interventions. Eur. J. Cancer 2002, 38(1):27-43.
121. Shuto H., Kataoka Y., Horikawa T., Fujihara N., Oishi R. Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain. Brain Res. 1997, 747:348-351.
122. Smith A.J., Humphries S.E. Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev. 2009, 20(1):43-59.
123. Solomayer E.F., Feuerer M., Bai L., Umansky V., Beckhove P., Meyberg G.C., Bastert G., Schirrmacher V., Diel I.J. Influence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer. Clin. Cancer Res. 2003, 9(1):174-180.
124. Steptoe A., Hamer M., Chida Y. The effects of acute psychological stress on circulating inflammatory factors in humans: a review and meta-analysis. Brain Behav. Immun. 2007, 21(7):901-912.
125. Stone H.B., Coleman C.N., Anscher M.S., McBride W.H. Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol. 2003, 4(9):529-536.
126. Taylor S.E., Lehman B.J., Kiefe C.I., Seeman T.E. Relationship of early life stress and psychological functioning to adult C-reactive protein in the coronary artery risk development in young adults study. Biol. Psychiatry 2006, 60(8):819-824.
127. Tyring S., Gottlieb A., Papp K., Gordon K., Leonardi C., Wang A., Lalla D., Woolley M., Jahreis A., Zitnik R., Cella D., Krishnan R. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006, 367(9504):29-35.
128. Van der Meeren A., Lebaron-Jacobs L. Behavioural consequences of an 8 Gy total body irradiation in mice. regulation by interleukin-4. Can. J. Physiol. Pharmacol. 2001, 79:140-143.
129. Van der Meeren A., Monti P., Lebaron-Jacobs L., Marquette C., Gourmelon P. Characterization of the acute inflammatory response after irradiation in mice and its regulation by interleukin 4 (Il4). Radiat. Res. 2001, 155:858-865.
130. Wang X.S., Shi Q., Williams L.A., Cleeland C.S., Mobley G.M., Reuben J.M., Lee B.N., Giralt S.A. Serum interleukin-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation. Cancer 2008, 113(8):2102-2109.
131. Wang X.S., Shi Q., Williams L.A., Mao L., Cleeland C.S., Komaki R.R., Mobley G.M., Liao Z. Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav. Immun. 2010, 24:968-974.
132. Wang, X.S., Williams, L.A, Krishnan, S, Liao, Z., Liu, P., Mao, L., Shi, Q., Mobley, G.M., Woodruff.,J.F., Cleeland, C.S., In press. Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy. Brain Behav. Immun, in press.
133. Weinrib A.Z., Sephton S.E., Degeest K., Penedo F., Bender D., Zimmerman B., Kirschbaum C., Sood A.K., Lubaroff D.M., Lutgendorf S.K. Diurnal cortisol dysregulation, functional disability, and depression in women with ovarian cancer. Cancer 2010, 116(18):4410-4419.
134. Wood L.J., Nail L.M., Perrin N.A., Elsea C.R., Fischer A., Druker B.J. The cancer chemotherapy drug etoposide (VP-16) induces proinflammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy-related symptoms. Biol. Res. Nurs. 2006, 8:157-169.
135. Wratten C., Kilmurray J., Nash S., Seldon M., Hamilton C.S., O'Brien P.C., Denham J.W. Fatigue during breast radiotherapy and its relationship to biological factors. Int. J. Radiat. Oncol. Biol. Phys. 2004, 59(1):160-167.
136. York J.M., Blevins N.A., Meling D.D., Peterlin M.B., Gridley D.S., Cengel K.A., Freund G.G. The biobehavioral and neuroimmune impact of low-dose ionizing radiation. Brain Behav. Immun. 2012, 26:218-227.